Cellyan Biotechnology (HKPD) Receivables (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Receivables came in at $4.9 million in Q3 2025, up 1.66% year-on-year from $4.8 million in Q3 2024, and up 3.23% on a QoQ basis from $4.7 million in Q1 2025.
Cellyan Biotechnology (HKPD) Receivables (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Receivables data on file, last reported at $4.9 million in Q3 2025.
- On a quarterly basis, Receivables rose 1.66% year-over-year to $4.9 million in Q3 2025; TTM through Sep 2025 was $4.9 million, a 1.66% increase from a year earlier, with the FY2025 full-year figure at $5.1 million, up 2.88% from the prior year.
- Receivables for Q3 2025 stood at $4.9 million, up from $4.7 million in the prior quarter.
- Over the last five years, Receivables for HKPD reached as high as $5.0 million in Q1 2024 and fell as low as $4.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | 31.98 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 24.89 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | 13.65 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 1.75 Bn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | 193.81 Mn |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | 36.61 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | 103.70 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | 21.84 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | 832,132.00 |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - | 4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.87 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Mar 31, 2024 | 4.96 Mn |